Second-Line Treatment of Advanced Non-small Cell Lung Cancer
Cesare Gridelli, Andrea Ardizzoni, Fortunato Ciardiello et al. · Journal of Thoracic Oncology · 2008
Cited by 69 works. doi:10.1097/jto.0b013e318168c815 Open-access PDF
Authors
- Cesare Gridelli
- Andrea Ardizzoni
- Fortunato Ciardiello
- Nasser H. Hanna
- John Victor Heymach
- Francesco Perrone
- Rafael Rosell
- Frances A. Shepherd
- N. Thatcher
- Johan Vansteenkiste
- Luigi De Petris
- Massimo Di Maïo
- Filippo de Marinis
References
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
- Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
- Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
- Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
- Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens